<DOC>
	<DOCNO>NCT02610361</DOCNO>
	<brief_summary>This study evaluate safety , tolerability , pharmacokinetic profile treatment effect new drug know BGB-283 patient solid tumour .</brief_summary>
	<brief_title>Study Safety Pharmacokinetics BGB-283 Patients With Solid Tumors</brief_title>
	<detailed_description />
	<criteria>1 . Provided write informed consent prior enrollment . 2 . Male female least 18 year age . 3 . A life expectancy least 12 week . 4 . Histologically cytologically confirm advanced metastatic solid tumor effective standard therapy available . 5 . One BRAF , NRAS , KRAS mutation positive solid tumor . 6 . Eastern Cooperative Oncology Group ( ECOG ) performance status ≤ 1 . 7 . Able swallow retain oral medication . 8 . Adequate bone marrow , liver , renal function : Hemoglobin &gt; 9 g/dL Absolute neutrophil count ≥ 1000/mm^3 Platelets ≥ 100,000/mm^3 Total bilirubin ≤1.5 time upper limit normal ( ULN ) Aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) ≤ 2.5 x ULN ( ≤ 5 x ULN subject know liver metastasis ) Creatinine clearance ≥ 45 mL/min ( calculate Cockcroft Gault formula ) . 9 . Female subject eligible enter participate study : ) Non childbearing potential ( i.e. , physiologically incapable become pregnant ) , include female ) Has hysterectomy , ii ) Has bilateral oophorectomy ( ovariectomy ) , iii ) Has bilateral tubal ligation , iv ) Is post menopausal ( total cessation menses ≥ 1 year ) . b ) Childbearing potential , negative serum pregnancy test screening ( within 7 day first investigational product administration ) , use adequate contraception study entry throughout study 28 day last investigational product administration . Adequate contraception , use consistently accordance product label instruction physician , define follow : ) Vasectomized partner sterile prior female subject 's entry sole sexual partner female . ii ) Any intrauterine device document failure rate le 1 % per year . iii ) Double barrier contraception define condom spermicidal jelly , foam , suppository , film ; OR diaphragm spermicide ; OR male condom diaphragm . 10 . Subjects treat brain metastasis eligible enter participate study neurologically stable . 1 . Female subject pregnant lactating . 2 . Subjects receive cancer therapy ( chemotherapy systemic anti cancer therapy , immunotherapy , radiation therapy , surgery ) time enrollment . 3 . Any major surgery within 28 day prior enrollment . 4 . Any radiotherapy within 14 day prior enrollment , provide subject recovered toxicity NCICTCAE ≤ Grade 1 . 5 . Use investigational anti cancer drug within 28 day first investigational product administration . 6 . Unresolved toxicity &gt; Grade 1 ( accord NCICTCAE , Version 4.03 ) previous anti cancer therapy , unless agree sponsor . 7 . History presence gastrointestinal disease condition know interfere absorption , distribution , metabolism , excretion drug . 8 . Known immediate delay hypersensitivity reaction idiosyncrasy drug chemically relate study drug component BGB283 . ( To date know Food Drug Administration [ FDA ] approve drug chemically relate BGB283 ) . 9 . Untreated leptomeningeal brain metastasis . Subjects previously treat brain metastasis asymptomatic , steroid longer 28 day permit . 10 . Any unstable , preexist major medical condition opinion Investigator contra indicates use investigational product , include active infection , know human immunodeficiency virus ( HIV ) positive subject , know Hepatitis B C. 11 . Psychological , familial , sociological , geographical condition permit compliance protocol . 12 . As result medical interview , physical examination screen investigation , investigator considers subject unfit study . 13 . Is medication list protocol require medication treatment BGB283 . 14 . Candidates curative therapy . 15 . Unable unwilling comply require treatment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>